However, resistance due to mechanisms such as BRCA gene mutation reversal reduces the clinical efficacy of PARP inhibitors, and HR-proficient cancers are not sensitive to PARP1 inhibitors (Lord and Ashworth, 2013; Lord and Ashworth, 2017; Ge et al., 2022). Here, PARP1 is linked to cancer.